Belinostat PTCL BELIEF Study

Belinostat (a drug owned by Spectrum Pharmaceuticals Inc. and TopoTarget A/S).

TopoTarget posted friday that the BELIEF study have beaten the primary endpoint by the study:

https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=522265&lang=en

Their Partner, Spectrum Pharmaceuticals didnt confirm those data, and there were some misunderstandings in the market. Today, spectrum announced the following comment about the BELIEF study.

http://finance.yahoo.com/news/spectrum-pharmaceuticals-provides-belinostat-registrational-112600330.html

For me, its clear, thare there are some misunderstandings in the partnerships between Spectrum and TopoTarget.